Asthma drug use and the development of Churg–Strauss syndrome (CSS)

Case reports suggest that leukotriene modifier use may be associated with the onset of Churg–Strauss syndrome (CSS). Using pooled data from two nested case‐control studies, we examined the association between asthma drug use and the development of CSS.

[1]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.

[2]  Judith K Jones,et al.  Public-released version of the Adverse Event Reporting System (AERS) database. , 2005, Clinical therapeutics.

[3]  A. Buist,et al.  Identification of patients with Churg–Strauss syndrome (CSS) using automated data , 2004, Pharmacoepidemiology and drug safety.

[4]  S. Eichner,et al.  Proposal to improve MedWatch: decentralized, regional surveillance of adverse drug reactions. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[5]  Richard Beasley,et al.  Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. , 2004, Clinical therapeutics.

[6]  E. Yelin,et al.  Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma? , 2004, Archives of internal medicine.

[7]  U. Specks,et al.  Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. , 2003, The American journal of medicine.

[8]  P. Weller,et al.  The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. , 2001, The Journal of allergy and clinical immunology.

[9]  R Platt,et al.  Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on therapeutics , 2001, Pharmacoepidemiology and drug safety.

[10]  R. Pauwels,et al.  Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. , 2000, Chest.

[11]  R. L. Green,et al.  Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment , 1999, The Lancet.

[12]  G. Hunder.  The Use and Misuse of Classification and Diagnostic Criteria for Complex Diseases , 1998, Annals of Internal Medicine.

[13]  T. Pincus,et al.  Limitations of the 1990 American College of Rheumatology Classification Criteria in the Diagnosis of Vasculitis , 1998, Annals of Internal Medicine.

[14]  D. Knoell,et al.  Churg-Strauss syndrome associated with zafirlukast. , 1998, Chest.

[15]  J. Drazen,et al.  Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. , 1998, JAMA.

[16]  R. Pauwels,et al.  Asthma therapies and Churg-Strauss syndrome. , 2002, The Journal of allergy and clinical immunology.